50th week of 2009 patent applcation highlights part 52 |
Patent application number | Title | Published |
20090305918 | GRAPHITE-CONTAINING HIGH-TEMPERATURE LUBRICANT FOR HIGH-GRADE STEELS AND CARBON STEELS - The present invention concerns a high-temperature lubricant for the hot shaping of high-grade and carbon steels, which has a content of graphite, organic blowing agent and inorganic separation agent, and the use thereof. In order to provide a high-temperature lubricant which can be used for a wide range of steel qualities for different wall thicknesses to be rolled and stretching effects and which is moreover stable in respect of temperature, provides constant rolling results upon a change in the wall thickness and/or the quality of steel and does not lead to unwanted cementation of the rolled material, the high-temperature lubricant according to the invention contains at least the following constituents in percent by weight with respect to the solids content:
| 2009-12-10 |
20090305919 | Multi-Dispersant Lubricating Composition - The present invention relates to a lubricating composition containing a corrosion inhibitor compound and a mixture of two or more dispersants, wherein 0 mole % to less than 50 mole % of the second dispersant molecules contain a carbocyclic ring. The invention further provides a method for lubricating a mechanical device using the lubricating composition. | 2009-12-10 |
20090305920 | LUBRICATING COMPOSITION - The present invention aims to offer a lubricating composition with excellent heat resistance, mechanical stability, water resistance, corrosion resistance, load resistance and flame resistance. To this end the present invention suggests that from 2 to 68% by weight of tricalcium phosphate relative to the total composition is added to a base oil, which may be a mineral oil and/or a synthetic oil. Surfactants are further added, and the whole is thoroughly mixed and kneaded to give a semi-solid lubricating composition. For the surfactants, non-ionic surfactants are most suitable, and fatty acid esters such as glycerine fatty acid esters, sorbitan fatty acid esters and sucrose fatty acid esters may be used. The amount used is from 0.2 to 18% by weight relative to the total composition. | 2009-12-10 |
20090305921 | LUBRICATING OIL COMPOSITION FOR DIESEL OIL VEHICLE - A lubricating oil composition for diesel oil vehicle comprises lubricating base oil, in which the composition further comprises triazine compound. The wheel rim power of the diesel oil vehicle is increased by 8-10%, the carbon smoke particulate discharge in tail gas is reduced by 30-50%, oil saving rate is high up to more than 10% and the oil change-over period of machine oil is 2-3 times of that of a conventional one; the discharge fully meets the standard, at the same time eliminates the bad smell and taste of the raw oil, the tail gas discharge of currently used vehicle or new vehicle meet the national standards by using the lubricating oil composition provided by the present invention. | 2009-12-10 |
20090305922 | LUBRICATING OIL COMPOSITION FOR AUTOMOBILE TRANSMISSION AND LUBRICATING METHOD USING SAME - The present invention relates to an automatic transmission lubricating oil composition, and particularly to an automatic transmission lubricating oil composition comprising an oil of lubricating viscosity, an ashless dispersant, an anti-oxidant, a phosphorus-based anti-wear agent and a friction-modifier, wherein more than 310 ppm of phosphorus is contained, thereby being useful for lubricating or operating an automatic transmission comprising a transmission clutch using a slip lock-up torque converter and a paper based clutch material and a planetary gear system, especially six-speed automatic transmission. | 2009-12-10 |
20090305923 | Dispersant Viscosity Modifiers Based on Maleic Anhydride-Styrene Copolymers - An interpolymer composition comprising monomer-derived units of (i) at least one of an aliphatic olefin containing from 2 to 30 carbon atoms and a vinyl aromatic monomer, and (ii) at least one alpha, beta-unsaturated acylating agent; wherein a portion of said acylating agent monomers is esterified and wherein a portion of said acylating agent monomers is condensed with at least one aromatic amine, provides good viscosity modification and dispersancy performance. | 2009-12-10 |
20090305924 | Method of Lubricating an Internal Combustion Engine - The present invention relates to a method of lubricating an internal combustion engine with a power output of at least 1600 kilowatts by supplying to the internal combustion engine a lubricating composition containing an oil of lubricating viscosity and at least 0.5 wt % of a hydrocarbyl-substituted carboxylic acid or anhydride thereof. The invention further provides a lubricating composition suitable for the method. | 2009-12-10 |
20090305925 | UTILIZATION OF AN ANHYDRIDE AS A DEMULSIFIER AND A SOLVENT FOR DEMULSIFIER FORMULATIONS - The present invention includes the use of anhydride compositions, including alkyl and aryl anhydrides, for use as a demulsifier in resolving emulsions of water and oil. In particular, the anhydride composition can be used alone or in a blend with other demulsifiers. Suitable anhydrides suitable for the present invention include acetic and propionic, with acetic anhydride being preferred. The anhydride composition can be added directly to crude oil or other compositions to be resolved. As such, the demulsifier composition includes an anhydride, such as acetic anhydride, alone or in combination with other demulsifiers. The anhydride can be used in an amount ranging between trace and 100% by weight of the demulsifier composition. | 2009-12-10 |
20090305926 | Pour Point Depressant for Hydrocarbon Compositions - Disclosed in one embodiment is a hydrocarbon blend made from 0.001 to 10 wt % of at least one poly-α-olefin, by weight of the blend, the at least one poly-α-olefin having a Kv | 2009-12-10 |
20090305927 | ORGANIC COMPOSITIONS - A hard-surface treatment composition comprising:
| 2009-12-10 |
20090305928 | Mixtures of Unsaturated Macrocyclic Epoxides as Odoriferous Substances - A mixture of 17-oxabicyclo[14.1.0]heptadec-8-ene and its isomers as an odoriferous substance and an odoriferous or aroma substance mixture comprising 17-oxabicyclo[14.1.0]heptadec-8-ene and one or more further odoriferous or aroma substances are described. | 2009-12-10 |
20090305929 | ACRYLIC POLYMER BASED PERSONAL CLEANSING COMPOSITION HAVING HIGH TRANSPARENCY, AND METHOD OF PROCESS - A composition and method for a cross-linked acrylic acid polymer based personal cleanser having high clarity is disclosed. Particular compositional ingredients are combined in a specified process such that the final composition comprises a clear, transparent personal cleansing product. | 2009-12-10 |
20090305930 | Use of hydrophobin for hard surface soil-repellent treatment - Use of hydrophobins for soil-repellent treatment of hard surfaces, in particular in combination with a cleansing of the surface, processes for soil-repellent treatment of hard surfaces, cleansing agents for hard surfaces and also hard surfaces with a soil-repellent coating comprising hydrophobins. | 2009-12-10 |
20090305931 | COMPOSITION FOR REMOVING AN INSULATION MATERIAL AND RELATED METHODS - A composition for removing an insulation material and related methods of use are disclosed. The composition comprises about 1 to 50 percent by weight of an oxidizing agent, about 0.1 to 35 percent by weight of a fluorine-containing compound, and water. The insulation material comprises at least one of a low-k material and a protection material. | 2009-12-10 |
20090305932 | COMPOSITION FOR REMOVING ENGINE DEPOSITS FROM TURBINE COMPONENTS - A method and cleaning composition for removing engine deposits from turbine components, in particular turbine disks and turbine shafts. This method comprises the following steps: (a) providing a turbine component having a surface with engine deposits thereon, wherein the turbine component comprises a nickel and/or cobalt-containing base metal; and (b) treating the surface of the turbine component with a cleaning composition to convert the engine deposits thereon to a removable smut without substantially etching the base metal of the turbine component. The cleaning composition comprises an aqueous solution that is substantially free of acetic acid and comprising: a nitrate ion source in an amount, by weight of the nitrate ion, of from about 470 to about 710 grams/liter; and a bifluoride ion source in an amount, by weight of the bifluoride ion, of from about 0.5 to about 15 grams/liter. The smut that is formed can be removed from the surface of the turbine component in a manner that does not substantially alter the surface thereof. | 2009-12-10 |
20090305933 | LOW INTERFACIAL TENSION SURFACTANTS FOR PETROLEUM APPLICATIONS - The invention relates to a class of novel surfactants that have utility in the recovery and/or extraction of oil. | 2009-12-10 |
20090305934 | Polymers and their use for inhibition of scale build-up in automatic dishwashing applications - The present invention provides a method of controlling scale in aqueous dishwashing systems which involves adding at least one high molecular weight terpolymer made from one or more monoethylenically unsaturated C | 2009-12-10 |
20090305935 | PRODUCTION OF GLUCOSE FROM STARCH USING ALPHA-AMYLASES FROM BACILLUS SUBTILIS - An α-amylase from | 2009-12-10 |
20090305936 | BLEACH COMPOSITIONS - Laundry or cleaning composition comprising: (a) a catalytically effective amount, preferably from about 1 ppb to about 99.9%, of a transition-metal bleach catalyst which is a complex of a transition-metal and a cross-bridged macropolycyclic ligand; and (b) at least about 0.1% of one or more laundry or cleaning adjunct materials, preferably comprising an oxygen bleaching agent. Preferred compositions are laundry compositions and automatic dishwashing detergents which provide enhanced cleaning/bleaching benefits through the use of such catalysts. | 2009-12-10 |
20090305937 | Detergent Composition - A detergent composition comprising:
| 2009-12-10 |
20090305938 | Production of Amine Oxide Granulates and the Use Thereof - Surfactant granulates containing 10 to 90 wt. % amine oxide, 10 to 90 wt. % carrier material and 0 to 50 wt. % binder can be manufactured by fluidized bed granulation and employed for upgrading a washing detergent or cleaning agent composition. The upgraded washing detergent or cleaning agent composition is characterized inter alia by an improved performance for the removal of fat-containing stains. | 2009-12-10 |
20090305939 | Detergent Composition - A detergent composition comprising at most 15% by weight of phosphate builder(s) and aluminosilicate builder(s), and comprising at least one short chain anionic surfactant selected from alkyl sulfate surfactant(s) and alkyl sulfonate surfactants. | 2009-12-10 |
20090305940 | Washing amd cleaning agents containing alcohol ethoxylate propoxylates - The invention relates to washing and cleaning agents that, as a washing active substance, contain alcohol ethoxylate propoxylates, which are obtained by the addition of ethylene oxide and propylene oxide to fatty alcohols, the number of the added propylene oxide units needing to be greater than the number of the added ethylene oxide units. | 2009-12-10 |
20090305941 | Foaming Hard Surface Cleaner - A foamable composition comprising: a) at least one anionic surfactant chosen from a salt of an alkyl sulfate and a salt of an alkyl ether sulfate in an amount of about 0.01 to about 1% by weight of the composition: b) at least one glycol ether in an amount of about 0.1 to about 1.5% by weight of the composition; c) at least one alcohol in an amount of about 2 to about 6% by weight of the composition; and d) water. Also, a foamable composition comprising: a) at least one anionic surfactant chosen from a salt of an alkyl sulfate and a salt of an alkyl ether sulfate; b) at least one glycol ether; c) at least one alcohol: and d) water, wherein the composition has a run down time of greater than about 15 seconds on a vertical glass surface across a distance of 10 cm. | 2009-12-10 |
20090305942 | Soaps Produced from Oil-Bearing Microbial Biomass and Oils - Soap and cosmetic products can be made from oil-bearing microbial biomass via the alkaline hydrolysis of glycerolipids and fatty acid esters to fatty acid salts. The saponified microbial oils/lipids can be combined with a variety of additives to produce compositions for use as soaps and other cosmetic products, which may also contain other constituents of the biomass, including unsaponified oils, glycerol and carotenoids, among others. | 2009-12-10 |
20090305943 | CYCLODEXTRIN BLENDS WITH CRYSTAL GROWTH INHIBITORS - The invention relates to the field of encapsulating aromas with cyclodextrins. In particular, it relates to methods for spray drying aromas to produce aroma/cyclodextrin particles and to the resultant particles themselves. | 2009-12-10 |
20090305944 | Methods for Providing Palliative Care with AVR 118 - The invention relates to methods for providing palliative care. Specifically, methods for treating patients having an end-stage disease, such as cancer, comprising administering an effective amount of AVR118 are disclosed. Pharmaceutical compositions and kits comprising AVR118, an additional medicament, and pharmaceutically acceptable carriers are also disclosed. The disclosed methods are useful for treating cachexia and/or improving the quality of life in patients near the end of life. | 2009-12-10 |
20090305945 | NOVEL NUTRACEUTICAL COMPOSITIONS - The present invention describes a composition which comprises a protein hydrolysate or a protein hydrolysate and one amino acid hydrolysate for the long term treatment or prevention of type 2 diabetes or pre-diabetes or metabolic syndrome or obesity. | 2009-12-10 |
20090305946 | METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISORDERS AND ALZHEIMER'S DISEASE AND IMPROVING NORMAL MEMORY - The disclosure relates generally to neurodegenerative disorders and more specifically to a group of presenilin/G-protein/c-src binding polypeptides and methods of use for modulating signaling and progression of Alzheimer's disease. | 2009-12-10 |
20090305947 | LIVESTOCK MANAGEMENT FOR IMPROVED REPRODUCTIVE EFFICIENCY - The present invention relates to methods for controlling the reproductive cycles and weaning in livestock, particularly to the use of casein-derived peptides for estrus induction and reduction of anestrus intervals, enabling early weaning without negatively affecting the livestock welfare. The present invention further relates to estrus synchronization in a livestock herd and to livestock management programs. | 2009-12-10 |
20090305948 | Branched Polyamino Acids Functionalized with Hydrophobic Groups, and Applications Thereof Particularly Therapeutic Applications - The invention concerns novel materials based on biodegradable branched polyaminoacids particularly useful for transporting active principle(s). The invention also concerns novel pharmaceutical, cosmetic, dietetic or phytosanitary compositions based on polyaminoacids. The invention aims at providing a novel polymeric material, capable of being used for transporting active principle(s) and enabling all the required relevant specifications to be optimally satisfied: biocompatibility, biodegradability, easy ability to be combined with a large number of active principles or to solubilize same, and to release said active principles in vivo. This is achieved by the present invention which firstly concerns branched polyaminoacids comprising aspartic acid units and or glutamic acid units, and which bear hydrophobic groups including 8 to 30 carbon atoms. Said branched polyaminoacids are amphiphilic and are capable of being easily and economically transformed into particles for transporting active principles, said particles being themselves capable of forming stable aqueous colloidal suspensions. | 2009-12-10 |
20090305949 | GLYCOSYLATED SPECIFICITY EXCHANGER - The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described herein. | 2009-12-10 |
20090305950 | MULTIMER OF EXTRACELLULAR DOMAIN OF CELL SURFACE FUNCTIONAL MOLECULE - As a substance which pharmacologically regulates the function of a cell surface functional molecule, a substance which has specificity and an activity or efficacy equal or superior to an antibody and does not require an advanced production technique and facility for application thereof to a pharmaceutical product has been demanded. The invention relates to a multimer of an extracellular domain of a cell surface functional molecule, particularly a tetramer of an extracellular domain of PD-1 or PD-L1. Further, the invention relates to an application of such a tetramer as a preventive and/or therapeutic agent for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of PD-1 or PD-L1 as a testing or diagnostic agent or a research agent for such a disease. | 2009-12-10 |
20090305951 | COMPOUNDS CAPABLE OF AFFECTING DIFFERENTIATION, PROLIFERATION, REGENERATION, PLASTICITY AND SURVIVAL CELLS - The present invention relates to a compound comprising the third Immunoglobulin (Ig3) module, and/or the fourth Immunoglobulin (Ig4) module, and/or the fifth immunoglobulin (Ig5) module, and/or the first Fibronectin III (Fn3,1) module, and/or the second Fibronectin III (Fn3,2) module of neural cell adhesion molecule (NCAM), or a fragment, or a variant thereof, capable of interacting with an Fibroblast Growth Factor (FGF) receptor and/or Adenosine-Tri-Phosphate (ATP) and/or L1, and thereby the compounds are capable of inducing differentiation, modulating proliferation, stimulate regeneration, neuronal plasticity and/or survival of cells. Further, the present invention relates to a pharmaceutical composition comprising said compound, a process of producing a pharmaceutical composition and the use of said compound. | 2009-12-10 |
20090305952 | Anionic polyamide functionalized with a tryptophan unit - The invention relates to an anionic polyamide functionalized with at least one tryptophan unit, -Trp, said tryptophan unit being linked to the polyamide by an amide function separated from the backbone by a linker arm, the polyamide being a chain selected from the group constituted of the following polymers: | 2009-12-10 |
20090305953 | DALBAVANCIN COMPOSITIONS FOR TREATMENT OF BACTERIAL INFECTIONS - The invention provides methods and compositions for treatment of bacterial infections. Methods of the invention include administration of a mixture of dalbavancin multimers and monomers for treatment of a bacterial infection, in particular a Gram-positive bacterial infection of skin and soft tissue. Compositions comprise a mixture of dalbavancin multimer and monomer and a stabilizer, such as dextrose. | 2009-12-10 |
20090305954 | HISTIDINE-CONTAINING DIASTEREOMERIC PEPTIDES AND USES THEREOF - Diastereomeric peptides with a net positive charge greater than +1, and cyclic derivatives thereof, are provided, having at least 13 amino acid residues, comprising histidine and one or more hydrophobic amino acid residues, optionally esterified or amidated at the C-terminus and/or acylated at the N-terminus. The peptides may contain other amino acid residues including non-natural amino acids. The peptides are particularly useful in the treatment of cancer. | 2009-12-10 |
20090305955 | Cyclopeptide with Anti-Cancer Activity Derived from Collagen Type IV - The present invention relates to a cyclopeptide characterized in that it comprises the YSNS amino acid sequence, and more particularly a cyclopentapeptide which forms a β-bend structure at the YSNS amino acids. In one specific embodiment, the cyclopeptide of the invention is capable of binding to the αVβ3-integrin. The application also claims the use of a cyclopeptide of the invention in the treatment of cancer, and more particularly in the treatment of the various forms of melanoma, and also in the manufacture of a medicament for treating cancer. Finally, the application describes the use of a cyclopeptide of the invention for inhibiting or reducing angiogenesis, and more particularly in tumours, and also in the manufacture of a medicament for inhibiting or reducing angiogenesis. | 2009-12-10 |
20090305956 | Treatment of Ras-Expressing Tumors - The present invention provides compositions and methods for the treatment of /?αs-expressing tumors using at least one DAC inhibitor (e.g., romidepsin). | 2009-12-10 |
20090305957 | PREPARATION OF BIODEGRADABLE POLYESTERS WITH LOW-BURST PROPERTIES BY SUPERCRITICAL FLUID EXTRACTION - The invention provides methods of extracting a biodegradable polyester with a supercritical fluid effective to obtain a purified biodegradable polyester, such as a purified biodegradable poly(lactide-glycolide) (PLG). The supercritical fluid can be carbon dioxide at an elevated pressure, or can be carbon dioxide with one or more cosolvents. Methods for carrying out stepwise purification of the biodegradable polyester at multiple pressures or multiple temperatures, or both, are also provided. When the polyester is PLG, a purified PLG copolymer is obtained having a narrowed molecular weight distribution with respect to the unpurified polyester. The purified PLG copolymer can have a polydispersity index of less than about 1.7, less than about 2% monomers, and less than about 10% oligomers. The purified PLG copolymer can exhibit a reduced initial burst effect when incorporated into a controlled release formulation such as a flowable implant adapted to be injected into body tissues. | 2009-12-10 |
20090305958 | STABILIZING ALKYLGLYCOSIDE COMPOSITIONS AND METHODS THEREOF - The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or analog thereof, for example parathyroid hormone (PTH) or PTH analogs, amylin, insulin, Peptide T or analog thereof, gastrin, gastrin releasing peptides, gastrin releasing peptide-like (GRP) proteins, epidermal growth factor or analog thereof. | 2009-12-10 |
20090305959 | Use of Peptidic Vasopressin Receptor Agonists - The present invention relates to the use of novel compounds for the manufacture of a medicament for treatment of, inter alia, conditions associated with critical care as well as to a method for treatment of said conditions, wherein said compounds are administered. The compounds utilised are represented by the general formula (I), as further defined in the specification. | 2009-12-10 |
20090305960 | Melanocortin Receptor-Specific Peptides for Treatment of Obesity / 669 - Melanocortin receptor-specific cyclic peptides of the formula | 2009-12-10 |
20090305961 | Novel chimeric plasminogen activators and their pharmaceutical use - The present invention relates to recombinant chimeric proteins comprising a surfactant protein precursor N-terminally fused to a plasminogen activator or comprising a mature surfactant protein N-terminally or C-terminally fused to a plasminogen activator. The invention is also directed to the corresponding nucleic acid molecules encoding such fusion proteins as well as to a method for their production. The invention further refers to a pharmaceutical composition comprising such a fusion protein and to pharmacological uses of an inventive fusion protein for the prevention and/or treatment of inflammatory and interstitial lung diseases. | 2009-12-10 |
20090305962 | IL-6 binding proteins - Polypeptides comprising monomer domains that bind to IL-6, or portions thereof, are provided. | 2009-12-10 |
20090305963 | Lipocalin 2 for the Treatment, Prevention, and Management of Cancer Metastasis, Angiogenesis, and Fibrosis - The invention features methods and compositions for treating and preventing cancer metastasis, angiogenic disorders, and fibrotic disorders using lipocalin 2 compounds. | 2009-12-10 |
20090305964 | PHARMACEUTICAL PREPARATIONS OF A GLP-1 MOLECULE AND AN ANTI-EMETIC DRUG - The present invention relates to a kit of parts comprising a GLP-1 molecule and an anti-emetic drug, said kit of parts being suitable for separate, sequential or/and simultaneous administration to a subject, preferably a human being. Also provided are combinations of GLP-1 or a GLP-1 analog with one or more anti-emetic drugs, as well as uses of the combinations in the manufacture of medicaments. | 2009-12-10 |
20090305965 | Stabilized Parathyroid Hormone Composition Comprising Parathyroid Hormone, Buffer and Stabilizing Agent - Disclosed relates to a stabilized parathyroid hormone (PTH) comprising a buffer and a stabilizing agent and, more particularly, to a stabilized PTH composition in which succinic acid, malic acid, histidine or ammonium bicarbonate is used as the buffer and sorbitol or mannitol is used as the stabilizing agent. The PTH composition of the present invention can be used to formulate stably PTH protein that is much more unstable to be readily decomposed than normal low molecular weight drugs. | 2009-12-10 |
20090305966 | Use of histones for therapeutic purposes - The invention relates to the use of at least one human recombinant histone, especially at least one histone H1 subtype, and/or a therapeutic histone fraction as a basis for the treatment of thrombocytopenia. | 2009-12-10 |
20090305967 | GLYCOPEGYLATED FACTOR VII AND FACTOR VIIA - The present invention provides conjugates between Factor VII or Factor VIIa peptides and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from both glycosylated and unglycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto either an amino acid or glycosyl residue on the peptide. Also provided are pharmaceutical formulations including the conjugates. Methods for preparing the conjugates are also within the scope of the invention. | 2009-12-10 |
20090305968 | Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway - The present invention refers to protein kinase inhibitors and more specifically to inhibitors of the protein kinase c-Jun amino terminal kinase. Additionally, the present invention provides JNK inhibitor sequences, chimeric peptides, nucleic acids encoding same as well as pharmaceutical compositions for treating pathophysiologies associated with JNK signaling. | 2009-12-10 |
20090305969 | Skin Repair Accelerating Therapeutic Agent Containing Desacyl Ghrelin and Derivatives Thereof as Active Ingredient - The present invention provides a novel therapeutic agent for skin injuries and a skin regeneration accelerator. The therapeutic agent for skin injuries and the skin regeneration accelerator containing desacyl ghrelin or a pharmaceutically acceptable salt thereof as an active ingredient. | 2009-12-10 |
20090305970 | Toxin-Like Polypeptides, Polynucleotides Encoding Same and Uses Thereof - An isolated polynucleotide is disclosed comprising a nucleic acid sequence encoding a polypeptide which comprises an amino acid sequence at least 90% identical to a sequence as set forth in SEQ ID NO: 1, wherein the polypeptide comprises an ion channel modulatory activity. Polypeptides and uses thereof are also disclosed. | 2009-12-10 |
20090305971 | Nogo-B Receptor - Nogo-B receptors bind to Nogo-B and mediate its biological function. We have discovered that Nogo-B receptor is a component of endothelial cells, and is highly expressed in intact blood vessels. The present invention provides compositions comprising the Nogo-B receptor and fragments and fusion proteins thereof. The present invention also relates to nucleic acids encoding the Nogo-B receptor and fragments and fusion proteins thereof, as well as vectors and cells comprising such nucleic acids. The present invention also relates to antibodies specific for the Nogo-B receptor and fragments and fusion proteins thereof. The present invention also provides methods for preventing, detecting and treating Nogo-B receptor-related diseases, disorders and conditions. | 2009-12-10 |
20090305972 | NOVEL CANCER-ASSOCIATED ANTIGEN - The present invention provides a novel cancer-associated antigen that can be used in the treatment and diagnosis of cancer. Further, the invention provides amino acid and nucleic acid sequence of the novel antigen, binding proteins, and immuno-conjugates. The invention also relates to diagnostic and therapeutic methods and kits. | 2009-12-10 |
20090305973 | NOVEL PEPTIDE AND USE THEREOF - The present invention relates to a novel peptide and use thereof, more particularly to an isolated peptide comprising 21-41 contiguous amino acids selected from the amino acid sequence of SEQ ID NO: 1 or the amino acid sequence having at least 90% sequence homology to the amino acid sequence of SEQ ID NO: 1 and methods for promoting fibroblast proliferation and wound healing, which comprise administering to a subject in need thereof an effective amount of the peptide. | 2009-12-10 |
20090305974 | THERAPEUTIC INDICATIONS OF COLONY STIMULATING FACTORS - The present invention relates to the use of at least one colony stimulating factor (CSF) for the production of medicinal products in the treatment or prophylaxis of coma or neurotoxicity. | 2009-12-10 |
20090305975 | Use of Trap Protein Per se as an Active Ingredient for the Manufacture of a Medicament for the Treatment of Staphylococcus Aureus Infection - Disclosed herein is the use of TRAP per se as an active ingredient for the manufacture of a medicament for the treatment of | 2009-12-10 |
20090305976 | Cytokine Mediating Composition - The invention relates to an agent having cytokine mediating activity. In particular the invention relates to a composition comprising a fraction of denatured plasma proteins and at least one metal, metal ion or metal salt thereof, wherein said mixture has cytokine mediating activity. | 2009-12-10 |
20090305977 | Method for treating peripheral arterial disease with zinc finger proteins - Disclosed is a method for the administration of zinc finger proteins (ZFPs) or nucleic acids that encode such ZFPs for treating peripheral arterial disease, particularly by the repeated administration at regular intervals if such ZFPs or nucleic acids that encode such ZFPs. | 2009-12-10 |
20090305978 | METHODS FOR INCREASING THE SIZE OF ANIMALS USING NEEDLELESS DELIVERY CONSTRUCTS - The present invention relates, in part, to methods for increasing the size of a subject by administering a delivery construct comprising growth hormone to a subject. In one aspect, the method for increasing the size of a subject by at least about 12% comprises contacting an apical surface of a polarized epithelial cell of the subject with an amount of a delivery construct comprising growth hormone that is effective to increase the size of the subject by at least about 12%. | 2009-12-10 |
20090305979 | COMPOSITIONS COMPRISING HPV POLYPEPTIDES AND IMMUNOENHANCEMENT PEPTIDES FOR THE TREATMENT AND PREVENTION OF CERVICAL CANCER - The present invention relates to a fusion protein comprising a fusion polypeptide of E6 and E7 of a human papilloma virus, a signal peptide for secreting the polypeptide out of the cell, and an immune enhancing peptide for a subject; a polynucleotide encoding the fusion protein; and a vector containing the polynucleotide. The present invention further relates to a pharmaceutical composition comprising the fusion protein or the vector; and a method for treating a disease caused by a human papilloma virus using the pharmaceutical composition. | 2009-12-10 |
20090305980 | Methods and Compositions Related to TR4 - Disclosed are compositions and methods related to TR4 and cancer. | 2009-12-10 |
20090305981 | SECRETED PROTEIN ACIDIC AND RICH IN CYSTEINE (SPARC) AS CHEMOTHERAPEUTIC SENSITIZERS - The present invention relates to compositions and methods of use thereof for cancer therapy sensitization. Such compositions comprise functional fragments of the nucleotide and/or polypeptide sequences of a Secreted Protein Acidic and Rich in Cysteine (SPARC). The compositions can be used in combination with existing chemotherapeutic agents for treatment of cancers. | 2009-12-10 |
20090305982 | MUTEINS OF TEAR LIPOCALIN AND METHODS FOR OBTAINING THE SAME - The present invention relates to novel muteins derived from human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein. | 2009-12-10 |
20090305983 | Curable Bone Cement - The present invention describes a curable bone cement. The cement comprises a curable polymeric binder and a filler, and is capable of curing without substantial evolution of heat on exposure to a curing agent. The binder comprises phenol groups which are capable of reacting in order to cure the cement. | 2009-12-10 |
20090305984 | Engineered CXCL 12 alpha locked dimer polypeptide - The present invention provides a novel CXCL12-α | 2009-12-10 |
20090305985 | Immunomodulatory Agents For Treatment of Inflammatory Diseases - The present invention provides methods and compositions suitable for treating inflammatory disorders such as allergy, asthma, artherosclerosis, autoimmune disease, infection, injury, meningitis, psoriasis, and transplant rejection. In particular, the present invention provides methods and compositions comprising human S100A8 and/or S100A9 for reducing inflammation. | 2009-12-10 |
20090305986 | FGF21 Mutants and uses thereof - The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions. | 2009-12-10 |
20090305987 | Method For Inducing Beta Cell Neogenesis From Epithelial Cells - The invention provides a method of inducing β-cell neogenesis from epithelial cells. The method includes the step of exposing epithelial cells that have a disrupted G1-S cell cycle transition to a hedgehog protein in an amount effective to stimulate β-cell neogenesis from the epithelial cells. Cells resulting from the method are insulin-positive and express pancreatic progenitor cell markers including Pdx-1 and ngn3. β-cell population expansion is observed when the method is carried out in either in vitro or in vivo settings. | 2009-12-10 |
20090305988 | MODIFIED PEPTIDE OF HUMAN ACIDIC FIBROBLAST GROWTH FACTOR - An modified peptide of human acidic fibroblast growth factor (aFGF), comprising a native human aFGF shortened by a deletion of a deletion of 20 amino acids from N-terminal of the native human aFGF, and an addition of alanine (Ala) before the shortened native aFGF is provided. | 2009-12-10 |
20090305989 | COMPOSITION AND METHOD FOR POTENTIATING DRUGS - A method of potentiating the activity of a drug which affects the central nervous system (CNS) comprising systemically administrating to a subject said drug together with an effective amount of a compound which stimulates peripheral chemoreceptors of vagal afferents and, optionally, with an effective amount of a stimulator of peripheral osmoreceptors of vagal afferents. Also disclosed are pharmaceutical compositions for systemic administration comprising a CNS drug together with the aforementioned compounds. | 2009-12-10 |
20090305990 | BI-LATERAL LOCAL RENAL DELIVERY FOR TREATING CONGESTIVE HEART FAILURE AND FOR BNP THERAPY - The invention relates to systems and methods for local renal delivery of agents to subjects that are at risk for congestive heart failure and other conditions. The invention encompasses devices for renal drug delivery and method of use. | 2009-12-10 |
20090305991 | 33 Human Secreted Proteins - The present invention relates to 33 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins. | 2009-12-10 |
20090305992 | USE OF AN INTERLEUKIN 1 RECEPTOR ANTAGONIST AND/OR PYRROLIDINEDITHIOCARBAMATE FOR THE TREATMENT OR PROPHYLAXIS OF TYPE 2 DIABETES - Substances that inhibit the action of the members of the IL-1β/NF-κB pathway can be used for protecting and preserving β-cell mass and function in prediabetic and diabetic type 2 patients. Specifically, the present invention relates to the use of an Interleukin 1 receptor antagonist (IL-1Ra) and/or pyrrolidinedithiocarbamate (PDTC) for the treatment or prophylaxis of type 2 diabetes, as well as a method for the treatment of type 2 diabetes. | 2009-12-10 |
20090305993 | METHODS AND COMPOSITION FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS - Pharmaceutical compositions comprising certain peptides that are capable of activating the guanylate-cyclase C (GC-C) receptor are described as are the peptides and method for using the peptides and pharmaceutical compositions for treating gastrointestinal disorders and other disorder. | 2009-12-10 |
20090305994 | Compounds Modulating Vegf Receptor and Uses Thereof - The present invention is related to the use of compounds which bind to the Vascular Endothelial Growth Factor Receptors and modulate the angiogenic response. The compounds, which mimic the VEGF amino acid region 17-25 involved in receptor recognition thereby inhibiting or stimulating the angiogenic process, can be used in the treatment of diseases characterized by excessive or defective angiogenesis VEGF-dependent, such as chronic ischemia, cancer, proliferative retinopathy and rheumatoid arthritis, states or conditions benefiting from the formation or regeneration of new vessels, as well as in the diagnosis of pathologies which present a overexpression of VEGF receptors or as biochemical tools to analyze the cellular pathways dependent on VEGF receptor activation. | 2009-12-10 |
20090305995 | AGONISTS AND ANTAGONISTS OF THE SOMATOSTATIN RECEPTOR - The invention relates to substituted F3-Phe-trp-F 3-Lys-beta-tri-peptides and derivatives thereof, a process for their preparation, pharmaceutical preparations which contain these compounds which are agonists/antagonists of somatostatin receptors, as active agents for the treatment of disorders which can be influenced by a modulation of somatostatin receptor activity, in particular somatostatin receptor sst4 activity, by the compounds of the invention. | 2009-12-10 |
20090305996 | USE OF NON-DIGESTABLE SACHARIDES FOR GIVING AN INFANT THE BEST START AFTER BIRTH - A food or supplement for pregnant women comprising water soluble, non-digestible saccharides is described. The composition is used to improve the flora and/or immune system of the pregnant women, to improve the immune system of the infant and to improve the intestinal flora of the infant after birth. | 2009-12-10 |
20090305997 | USE OF A GALACTOSE-DERIVED C-GLYCOSIDE COMPOUND AS AN AGENT FOR ACTIVATING AND REGULATING CUTANEOUS IMMUNITY - The present invention relates to a novel galactose derivatives of general formula (I) and to their use as agents for stimulating the immune system of the skin and/or as immunoregulators, and for preparing a composition containing a cosmetically or pharmaceutically acceptable medium, intended in particular to prevent and/or limit the appearance of cutaneous immune imbalances, in particular related to environmental stresses. | 2009-12-10 |
20090305998 | HSP90 INHIBITORS - The invention relates to HSP90 inhibiting compounds consisting of the formula: | 2009-12-10 |
20090305999 | UTILIZATION OF HYPERTENSION/HYPERCARDIA-PREVENTING EFFECT OF D-ALLOSE - The object is to provide a novel application of D-allose (e.g., use for prevention of hypertension or hypercardia). Thus, disclosed is a composition for preventing the increase in blood pressure which comprises D-allose as an active ingredient; or a composition containing D-allose and/or a derivative thereof, preferably in an amount of 0.1 to 50% by weight. Preferably, the composition is in a form selected from the group consisting of a food additive, a food material, a beverage/food, a health beverage/food, a pharmaceutical and a feeding stuff which can be used for the prevention and treatment of a cardiovascular system disorder (e.g., hypertension, hypercardia). The increase in blood pressure may be caused by salt-sensitive hypertension. Also disclosed is use of D-allose for preventing the increase in blood pressure (excluding medical practices). | 2009-12-10 |
20090306000 | TANAPROGET DERIVATIVES, METABOLITES, AND USES THEREOF - A method of generating synthetic metabolites of tanaproget derivatives thereof is provided. These compounds and methods of using these derivatives for detecting tanaproget metabolites in samples are provided. | 2009-12-10 |
20090306001 | NOVEL AMPHIPHILIC DERIVATIVES OF ALPHA-C-PHENYL-N-TERT-BUTYLNITRONE - Compounds derived from α-C-phenyl-N-tert-butylnitrone, a process for the preparation thereof and use thereof for the preparation of medicaments for use in preventing or treating oxidative stress-related diseases. | 2009-12-10 |
20090306002 | IRON METABOLISM-IMPROVING AGENT - An acetic acid- and/or acetate salt-free iron metabolism-improving agent that contains citric acid and/or a citrate salt as electrolytes and also contains another/other electrolyte/electrolytes and glucose solely or in combination is provided. The iron metabolism-improving agent can be formulated into a dialysate and/or a substitution fluid. A method for improving internal iron metabolism and a blood purification method including hemodialysis and hemodiafiltration in a chronic renal failure patient employing the dialysate and/or the substitution fluid are further provided. | 2009-12-10 |
20090306003 | Pesticide Delivery System - An improved pesticide delivery system is disclosed. The system is based on a microblend comprising (a) an amphophilic compound containing at least one hydrophilic group and at least one hydrophobic group and (b) a second compound. Compositions based on the microblend and methods of using the compositions to control pests are also disclosed. | 2009-12-10 |
20090306004 | GRAFTED MACROMOLECULAR CONJUGATES OF DOXORUBICIN WITH ANTICANCER ACTIVITY AND METHOD OF THEIR PREPARATION - A polymeric drug, in which a cancerostatic connected via spacers containing hydrolytically cleavable hydrazone bonds is bound to a water-soluble polymeric carrier prepared on the basis of a N-(2-hydroxypropyl)methacrylamide copolymer, wherein the structure of the polymeric drug consists of the main chain of N-(2-hydroxypropyl)methacrylamide carrying the cancerostatic and another chain of N-(2-hydroxypropyl)methacrylamide—a graft, which may also carry a cancerostatic, said grafts being bound to the main chain by a bond that is stable in the body and/or by a bond cleavable in the body, especially by an oligopeptide spacer selected from the series of GlyLeuGly, GlyPheGly, GlyPheLeuGly and GlyLeuPheGly, and a method of its preparation. | 2009-12-10 |
20090306005 | COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF PCSK9 - The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing. | 2009-12-10 |
20090306006 | USE OF NICOTINIC ACID ADENINE DINUCLEOTIDE PHOSPHATE OR DERIVATIVE THEREOF AS AGENT FOR TREATING TYPE-2 DIABETES - Nicotinic acid adenine dinucleotide phosphate and a pharmaceutically acceptable derivative thereof are useful for the treatment of type-2 diabetes. | 2009-12-10 |
20090306007 | NUCLEOSIDES WITH ANTIVIRAL AND ANTICANCER ACTIVITY - The invention provides a compound of formula (I), wherein R | 2009-12-10 |
20090306008 | 3'-ETHYNYLCYTIDINE DERIVATIVE - To provide a compound which exhibits excellent anti-tumor activity and excellent oral absorption and which is a useful anti-tumor drug. | 2009-12-10 |
20090306009 | Modulation of the P2Y2 Receptor Pathway - The present invention relates to the field of regulating the activity of the purinergic receptors for the modulation of the vascular tone, particularly for the purpose of treatment of haemodynamic conditions by overriding of vasoconstriction activity, such as increases in sympathic vasoconstriction. Modulators, such as UTP analogues as described herein are preferably specific for P2Y2. Compounds capable of stimulating the P2Y2 receptor are suitable for the treatment or prevention wherein inhibition of vasoconstriction activity is desirable such as hypertension and hypertension relates disorders or diseases, whereas compound capable of counteracting the activity of the P2Y2 receptor are suitable for the treatment of or prevention wherein inhibition of vasodilatation is desirable. | 2009-12-10 |
20090306010 | P1-(2'-DEOXYCYTIDINE 5'-)P4-(URIDINE 5'-)TETRAPHOSPHATE, TETRA-(ALKALI METAL) SALT, FOR TREATING DISORDERS - The present invention provides a method of treating edematous retinal disorders. The method comprises administration of a pharmaceutical formulation comprising a hydrolysis-resistant P2Y receptor agonist to stimulate the removal of pathological extraneous fluid from the subretinal and retinal spaces and thereby reduce the accumulation of said fluid associated with retinal detachment and retinal edema. The P2Y receptor agonist can be administered with therapeutic and adjuvant agents commonly used to treat edematous retinal disorders. The present invention also provides a method of treating cystic fibrosis. The present invention also provides a method of treating sinusitis. The present invention further provides P | 2009-12-10 |
20090306011 | Use Of An Alkyl Glycoside Or Of A Mixture Of At Least Two Alkyl Glycosides As Agent Intended For Inhibiting Microbial Growth, And Compositions Containing It - The present invention relates to the use of an alkyl glycoside or of a mixture of at least two alkyl glycosides as agent intended for inhibiting microbial growth, in particular in a cosmetic, pharmaceutical or food composition. | 2009-12-10 |
20090306012 | THERAPEUTIC PROTOCOLS - The present invention relates to the field of chemotherapy of diseases such as cell proliferation disorders including cancer. In particular, the present invention relates to the use of hyaluronan (HA) as a protective agent in the treatment of subjects. HA is administered in conjunction with a chemotherapeutic agent to facilitate the prolonged administration of a dose of the chemotherapeutic agent to be administered to a subject. Owing to the protective effects of the HA, the dose of chemotherapeutic agent may be substantially higher than a generally accepted effective dose, which would otherwise be expected to cause unacceptable side effects in the subject. | 2009-12-10 |
20090306013 | Drugs and Food Products for Hypophosphoric Normo-,Hyper-and Hypoproteic Diets, and Hypophosphoric Beverages - The present invention relates to an alimentary component comprising a physiologically acceptable phosphorus binding agent, in particular polyallylamine hydrochloride, polyallylamine carbonate, lanthanum carbonate, aluminium hydroxide, magnesium acetate, magnesium carbonate, calcium carbonate, calcium acetate, calcium citrate, calcium alginate, styrene divinyl-benzene ionic exchange resin, stabilized polynuclear iron hydroxide, calcium acetate plus magnesium carbonate and chitosan. Said component is useful in the nutrition of subjects in need of a low phosphorus level diet. | 2009-12-10 |
20090306014 | C-10 CARBAMATES OF TAXANES - Provided herein are C-10 taxane carbamates and pharmaceutically acceptable derivatives thereof. In certain embodiments, provided herein are compounds, compositions and methods for treating cancer and taupathy. | 2009-12-10 |
20090306015 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HIGHLY LIPOPHILIC SULFHYDRYL COMPOUNDS - Novel compositions of silicon-containing sulfhydryl compounds, their preparation and use in methods for treating disease are described. Silicon confers lipophilicity that can enhance the penetration of the silicon derivative sulfhydryl compounds across the gut wall, cell membranes and blood brain barrier, thus improving therapeutic properties including bioavailability, metabolism, and/or pharmacokinetics. The organosilyl group provides compounds having improved pharmacokinetics. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for treatment of diseases and other maladies or conditions and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes. | 2009-12-10 |
20090306016 | FATTY ACID AMIDE HYDROLASE INHIBITORS - Disclosed are compounds of formula R—X—Y that may be used to inhibit the action of fatty acid amide hydrolase (FAAH). Inhibition of fatty acid amide hydrolase (FAAH) will slow the normal degradation and inactivation of endogenous cannabinoid ligands by FAAH hydrolysis and allow higher levels of those endogenous cannabinergic ligands to remain present. These higher levels of endocannabinoid ligands provide increased stimulation of the cannabinoid CB1i and CB2 receptors and produce physiological effects related to the activation of the cannabinoid receptors. They will also enhance the effects of other exogenous cannabinergic ligands and allow them to produce their effects at lower concentrations as compared to systems in which fatty acid amide hydrolase (FAAH) action is hot inhibited. Thus, a compound that inhibits the inactivation of endogenous cannabinoid ligands by fatty acid amide hydrolase (FAAH) may increase the levels of endocannabinoids and, thus, enhance the activation of cannabinoid receptors. Thus, the compound may not directly modulate the cannabinoid receptors but has the effect of indirectly stimulating the cannabinoid receptors by increasing the levels of endocannabinoid ligands. It may also enhance the effects and duration of action of other exogenous cannabinergic ligands that are administered in order to elicit a cannabinergic response. | 2009-12-10 |
20090306017 | Methods and compositions for modulation of innate immunity - The present invention is directed towards a method of modulation of the innate immune of an organism system with the phosphorylated polyprenols of the present invention. The present invention is also directed towards a method of activation and/or modulation of the Toll-like Receptors with the phosphorylated polyprenols of the present invention. The present invention is also directed towards compound(s) comprising C35-C90 polyisoprenyls of Formula 1 and Formula 2 and their derivatives as well as methods of use of including activation and/or modulation of TLRs including TLR-2 and TLR-4 receptors and uses thereof including, e.g., use as antimicrobial, immunoregulatory, anti-cancer, cancer, for control of inflammatory conditions and as vaccine adjuvants. | 2009-12-10 |